June 20th 2025
The FDA has extended the review of ruxolitinib for atopic dermatitis in children 2 to 11 years to September 2025 to evaluate new CMC data.
Mechanism of Action for Agents Used to Treat Pediatric Atopic Dermatitis
Joshua Zeichner, MD, and Raj Chovatiya, MD, PhD, dive deep into the pathogenesis of atopic dermatitis and discuss how agents treating atopic dermatitis work.
Characteristics of Type 2 Inflammation and the Impact of Itch
Joshua Zeichner, MD, and Vikash Oza, MD, discuss characteristics of type 2 inflammation and the impact of itching on pediatric patients with atopic dermatitis.
Dupilumab may benefit skin barrier function in patients with atopic dermatitis
June 6th 2022A poster presented at the 2022 Fall Clinical Dermatology Conference for PAs & NPs showed normalization of skin barrier function in patients with moderate to severe atopic dermatitis taking dupilumab, according to the investigators.
How can digital therapeutic interventions improve symptoms of atopic dermatitis?
April 13th 2022What role will digital therapeutic agents have in the coming years of atopic dermatitis treatment? It’s still being studied, but Jonathan Silverberg, MD, reviewed an interventional study that may provide key insights into what’s to come.
Impact of dupilumab on quality of life in kids 6 months to 5 years
April 11th 2022An abstract presented at the Revolutionizing Atopic Dermatitis meeting discussed the impact of treatment with dupilumab on the quality of life for children aged 6 months to 5 years with atopic dermatitis, as well as their caregivers.
What you need to know about atopic dermatitis
April 12th 2021Atopic dermatitis is a chronic, inflammatory skin condition that affects 15% to 20% of children and 1% to 3% of adults in the United States. The prevalence of atopic dermatitis, which is also known as eczema, is increasing in developing and industrialized countries.